Drug Profile
Long-acting muscarinic antagonist - Viatris/Pfizer
Latest Information Update: 08 Dec 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Viatris Inc
- Class Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Respiratory-tract-disorders in USA (Inhalation)
- 18 Dec 2013 Clinical trials in Respiratory tract disorders in USA (Inhalation)